Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zevra Therapeutics, Inc. (ZVRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, Zevra uses current reports on Form 8-K and other periodic filings to communicate material events, financial results, and governance changes related to its rare disease business.
Investors can review Form 8-K filings in which Zevra reports quarterly financial results and corporate updates, including revenue from its commercial products for Niemann-Pick disease type C and certain urea cycle disorders, operating expenses, and information about conference calls and webcasts. Other 8-K filings detail matters such as the resignation and transition of key officers, appointment of interim financial leadership, and board-level changes, along with summaries of related agreements and compensation terms.
These filings also document equity inducement awards granted under Zevra’s employment inducement award plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing transparency into stock option grants to new employees. Together with annual and quarterly reports (when available), the filings offer a structured view of Zevra’s financial condition, capital structure, and risk disclosures as it advances therapies like MIPLYFFA and OLPRUVA and develops candidates such as celiprolol.
On Stock Titan, SEC documents are supplemented with AI-powered summaries that explain the key points of lengthy filings in plain language. Real-time updates from EDGAR help users see new Zevra filings as they appear, while specialized views of Forms 3, 4, and 5 make it easier to track insider transactions. For long-form reports such as 10-K and 10-Q, AI-generated highlights can help users quickly identify important sections on revenue drivers, research and development spending, and material risks related to Zevra’s rare disease portfolio.
Zevra Therapeutics reports 2025 commercial and corporate progress: $106.5 million in net revenue, including $87.4 million from MIPLYFFA® (arimoclomol), and recorded 161 MIPLYFFA enrollment forms. The company sold a Rare Pediatric Disease Priority Review Voucher for $150 million, expanded global access including an EAP for 113 patients, and advanced a Phase 3 trial with ~one-third enrolled. The 2026 Annual Meeting will be held virtually on June 4, 2026; the record date was April 6, 2026.
The Board recommends electing two Class II directors, ratifying EY as auditor, and approving declassification to annual director elections beginning after 2029.
Zevra Therapeutics Inc Schedule 13G/A amendment reports that The Vanguard Group holds 0 shares of Common Stock and 0% beneficial ownership following an internal realignment. The filing explains certain Vanguard subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538, and Vanguard no longer is deemed to beneficially own those securities.
Zevra Therapeutics director John B. Bode exercised stock options to acquire 78,400 shares of common stock. On March 24, 2026, he exercised two option grants covering 39,200 shares each at exercise prices of $4.97 and $4.89 per share.
Following these exercises, Bode directly owns 123,400 shares of Zevra Therapeutics common stock. The transactions were reported as derivative exercises rather than open-market purchases or sales, indicating a shift from options-based compensation into outright share ownership.
Zevra Therapeutics, Inc. reported that its CFO, Justin A. Renz, received a grant of stock options to purchase 300,000 shares of common stock. The options have an exercise price of $9.55 per share, equal to the closing market price on March 18, 2026, and expire ten years after the grant date.
The award was made under Zevra’s 2023 Employment Inducement Award Plan and vests in four equal annual installments beginning on the first anniversary of the grant, subject to continued service. All underlying shares will vest in full immediately before a change of control, and vesting will be accelerated by 12 months if the CFO is terminated without cause or resigns for good reason.
ZEVRA THERAPEUTICS, INC. filed an insider ownership report identifying Justin A. Renz as its CFO and reporting person. The data show no reported purchases, sales, acquisitions, dispositions, exercises, gifts, tax withholdings, or restructuring transactions, and no listed derivative positions or holdings in this filing.
R. LaDuane Clifton reported proposed dispositions of Common Stock under a Form 144, including sales disclosed for 02/03/2026 of 11,000 shares and for 01/30/2026 of 3,000 shares.
The filing lists multiple prior and scheduled issuances or vesting events (restricted stock vesting and previously exercised options) with amounts shown in the excerpt, including a 230,306 share entry for 03/10/2026 and larger vesting entries on 01/31/2025 and 12/31/2025. The filing shows addresses and broker/issuer information for the transactions.
Zevra Therapeutics has entered into an Asset Purchase and Settlement Agreement with Commave Therapeutics, under which Commave will buy Zevra’s SDX portfolio, including AZSTARYS® (KP415) and KP1077, for $50.0 million in cash. Commave will pay $25.0 million at signing, $20.0 million within ten business days of the effective date, and $5.0 million within three days after delivery of specified manufacturing and patent records.
The deal terminates the 2019 AZSTARYS License Agreement and settles Delaware Chancery Court litigation between the parties, with mutual releases and a dismissal with prejudice to be filed. Zevra also repaid in full approximately $63.0 million outstanding under its senior secured term loan, and states this has resulted in a strong, debt-free balance sheet and greater financial and strategic flexibility.
Zevra Therapeutics, Inc. (ZVRA) is a commercial-stage rare disease company focused on expanding access to treatments for underserved patient populations. The company’s lead product, MIPLYFFA (arimoclomol), became the first FDA‑approved therapy for Niemann‑Pick disease type C in September 2024 and is marketed in combination with miglustat in the United States. Zevra also runs a global expanded access program and has filed a Marketing Authorization Application in the European Union, now under EMA review.
Following approval, Zevra received and then sold a rare pediatric disease priority review voucher, generating $148.3 million of net proceeds that strengthen its balance sheet. The acquisition of Acer Therapeutics in 2023 added OLPRUVA for urea cycle disorders and the late‑stage celiprolol program for Vascular Ehlers‑Danlos syndrome, where a Phase 3 event‑driven trial (DiSCOVER) had 52 enrolled participants as of December 31, 2025. Zevra also earns royalties and potential milestones from the ADHD drug AZSTARYS and is advancing KP1077 for idiopathic hypersomnia and narcolepsy, supported by orphan designation and a Phase 2 trial that informed Phase 3 dosing plans.
Zevra Therapeutics reported a strong turnaround for 2025, with net revenue of $106.5 million, up from $23.6 million in 2024, driven mainly by $87.4 million in MIPLYFFA net revenue and higher expanded‑access and royalty income.
The company generated 2025 net income of $83.2 million, or $1.40 basic EPS, compared with a prior-year net loss of $105.5 million, helped by a $148.3 million gain on sale of a priority review voucher and despite a $58.7 million intangible asset impairment.
Q4 2025 net revenue reached $34.1 million and net income was $12.2 million. Cash, cash equivalents and securities totaled $238.9 million as of December 31, 2025, supporting continued investment in MIPLYFFA, OLPRUVA and the celiprolol VEDS program.
The company highlighted progress for MIPLYFFA in Niemann‑Pick type C, including growing U.S. uptake and an EMA marketing application under review, and ongoing enrollment in the Phase 3 DiSCOVER trial for celiprolol. Zevra also relocated its headquarters to Boston and appointed Justin Renz as Chief Financial Officer, with a $520,000 base salary and options to purchase 300,000 shares vesting over four years.
Zevra Therapeutics President and CEO Neil F. McFarlane reported equity award vesting and a planned share sale. On February 7, 2026, 37,500 restricted stock units vested, converting into the same number of common shares as part of an award that vests in three annual installments.
On February 9, 2026, McFarlane sold 14,625 shares of common stock at a weighted average price of $8.5597 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 21, 2025. Following these transactions, he directly holds 387,225 common shares and 75,000 restricted stock units.